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Abstract
Introduction: We examined whether plasma C-reactive protein (CRP) levels at the time of diagnosis of breast
cancer are associated with overall survival, disease-free survival, death from breast cancer, and recurrence of breast
cancer.
Methods: We observed 2,910 women for up to seven years after they were diagnosed with invasive breast cancer
(median follow-up time was three years). Plasma levels of high-sensitivity CRP were measured at the time of
diagnosis and we assessed the association between CRP levels and risk of reduced overall and disease-free survival,
death from breast cancer, and recurrence of breast cancer by using the Kaplan-Meier method and Cox
proportional hazards regression. During follow-up, 383 women died (225 of whom died from breast cancer) and
118 women experienced recurrence of breast cancer.
Results: Elevated CRP levels across tertiles at the time of diagnosis were associated with reduced overall and
disease-free survival and with increased risk of death from breast cancer (log-rank trend for all, P < 0.001), but not
with recurrence. The multifactor-adjusted hazard ratios (HR) of reduced overall survival among women in the
middle and highest versus the lowest tertile of CRP were 1.30 (95% CI, 0.97 to 1.73) and 1.94 (1.48 to 2.55),
respectively. Corresponding HRs of reduced disease-free survival were 1.16 (0.89 to 1.50) and 1.76 (1.38 to 2.25) and
of death from breast cancer 1.22 (0.84 to 1.78) and 1.66 (1.15 to 2.41). Dividing CRP levels into octiles resulted in a
stepwise increased risk of reduced overall survival (P for trend <0.001) and the multifactor-adjusted HR among
women in the highest versus the lowest octile of CRP was 2.51 (1.53 to 4.12). Compared to women with CRP levels
in the 0 to 25% percentile (<0.78 mg/L), the multifactor-adjusted HR of reduced overall survival among women
with CRP levels ≥95% percentile (≥16.4 mg/L) was 3.58 (2.36 to 5.42). Among women with HER2-positive tumours,
the multifactor-adjusted HR of reduced overall survival for the highest versus the lowest tertile of CRP was 8.63
(2.04 to 36.4).
Conclusions: Elevated CRP levels at the time of diagnosis of breast cancer are associated with reduced overall and
disease-free survival and with increased risk of death from breast cancer.
Introduction
Elevated plasma levels of C-reactive protein (CRP) may
be associated with poor prognosis after breast cancer.
CRP is a classical acute-phase protein displaying rapid
and pronounced rise of its plasma concentration in
response to acute inflammation, infection, and tissue
damage [1,2]. Circulating levels of CRP are also
moderately elevated during chronic inflammatory dis-
eases and cancer [3]. CRP is produced in the liver, pre-
dominantly under transcriptional control by the
cytokine interleukin-6 originating from the site of
pathology [4]. Many tumours arise at sites of chronic
inflammation or they trigger inflammatory responses
that result in the formation of an inflammatory micro-
environment around the tumour [5-9]. In fact, it has
recently been suggested that cancer-related inflamma-
tion may represent the seventh hallmark of cancer in
addition to the six hallmarks identified by Hanahan and
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environment stimulates tumour growth, invasion, and
metastasis, inflammation seems to favour invasion and
metastasis more than to mount an effective host anti-
tumour response [5-9].
Previous epidemiologic studies have reported that ele-
vated CRP levels may be associated with poor prognosis
of several types of solid cancers [10], including endome-
trial [11], cervical [12], colorectal, pancreatic, hepatocel-
lular, esophageal, renal cell, bladder, prostate, ovarian,
and non-small-cell lung cancer [13,14]. Although breast
cancers rarely are characterized by significant histologi-
cal inflammation, emerging evidence nevertheless sug-
gests that inflammatory pathways also play an important
role in breast cancer progression [15-20]. However,
results from prospective epidemiologic studies are con-
flicting, with some studies showing an association
between elevated CRP levels and poor prognosis [21-24]
and others showing no association [25,26]. The largest
study so far comprised 700 women treated successfully
for early stage breast cancer and found that elevated
levels of CRP measured two and a half years after the
time of diagnosis were associated with reduced disease-
free and overall survival [23]. Thus, it is unclear whether
CRP levels measured at the time of diagnosis are asso-
ciated with breast cancer prognosis.
We used a prospective cohort study of 2,910 patients
with invasive breast cancer to examine whether plasma
CRP levels at the time of diagnosis of breast cancer are
associated with overall survival, disease-free survival,
death from breast cancer, and recurrence of breast
cancer.
Materials and methods
Patients
We studied patients with invasive breast cancer from
the Copenhagen Breast Cancer Study, which is an
ongoing cohort study of Danish breast cancer patients.
Since January 2002, all patients that are referred to the
Department of Breast Surgery, Herlev Hospital, Copen-
hagen University Hospital with suspected breast cancer
are asked to participate in the study (participation rate
93%). At study enrolment the patients answer a ques-
tionnaire regarding sociodemographic factors, lifestyle
factors, anthropometric characteristics, medical history,
and family history of cancer. Furthermore, they give
blood for measurements of biochemical parameters.
In the present study, we included patients who were
diagnosed with breast cancer in the period 1 January
2002 until 31 January 2009 (n = 3,634) (Figure 1). Since
our intention was to study the association between CRP
levels and prognosis among women with invasive breast
cancer, we excluded patients without a measurement of
CRP (n = 131), men (n = 23), and women with in situ
breast cancer (n = 135). To avoid potential bias by the
influence of surgery on CRP levels, we also excluded
women who underwent breast cancer surgery before
blood sampling (n = 137). Finally, to ensure that plasma
CRP was measured at the time of diagnosis, we excluded
women who had plasma CRP measured more than 30
days before or after the date of diagnosis of breast can-
cer (n = 298). Thus, we included 2,910 women aged 26
to 99 years in the analysis of overall survival. For the
analysis of disease-free survival and recurrence, we addi-
tionally excluded 72 women for whom information
about recurrence was missing, 15 individuals who,
according to the register, had recurrence less than 90
days after their date of diagnosis, and 40 women who
had distant metastasis at diagnosis. The latter two
groups were excluded to ensure that the registered
recurrences were indeed true recurrences. Thus, 2,783
women aged 26 to 99 years were included in the analy-
sis of disease-free survival and recurrence. For the analy-
sis of death from breast cancer, we excluded 38 women
who were enrolled after 31 December 2008, since we
did not have information about cause-specific death
after this date. Thus, we included 2,872 women aged 26
to 99 years in the analysis of death from breast cancer
(Figure 1). Follow-up time for each patient began at
blood sampling and ended for overall survival at occur-
rence of death, emigration, or May 2009, whichever
came first. For disease-free survival and recurrence, fol-
low-up time ended at occurrence of recurrence, death,
emigration, or May 2009, whichever came first. For
death from breast cancer, follow-up time ended at death
from breast cancer, death from other causes, emigration,
or December 2008, whichever came first. The median
follow-up period was three years (range = 0 to 7 years).
During follow-up, 383 women died, 225 women died
from breast cancer, 118 women experienced recurrence
of breast cancer, and 4 women emigrated.
Register information
Information about diagnoses and prognostic tumour
characteristics (tumour size, lymph node status, pre-
sence of distant metastases, tumour grade, and estrogen
receptor, progesterone receptor, and HER2 status) of
index breast cancers was obtained from the national
Danish Breast Cancer Cooperative Group (DBCG) [27].
Diagnoses and prognostic tumour characteristics were
pathologically verified by clinical pathologists. Date of
recurrence was obtained from DBCG and date of death
and emigration was obtained from the national Danish
Civil Registration System, which is 100% complete.
Information about death from breast cancer was
obtained from the National Danish Causes of Death
Registry in which all death certificates in Denmark are
registered. Danish death certificates register courses of
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cause of death being the disease which started this
course. In the present study, patients who were regis-
tered with the World Health Organization (WHO)
International Classification of Diseases (ICD), Tenth
Revision (ICD-10) codes C50.0 to C50.9 as the underly-
ing cause of death were recorded as having died from
breast cancer.
Information about diagnosis of cardiovascular diseases
was obtained from the national Danish Patient Registry
which all public and private hospitals in Denmark report
to. Diagnoses were classified according to the WHO
ICD, Eighth Revision (ICD-8 codes 410 to 414 and 432
to 435) or Tenth Revision (ICD-10 codes I20 to I25 and
I63 to I64 and G45).
Ethics
The ethical committee of Copenhagen and Frederiks-
berg, Denmark approved the study (KA-02152). All
patients gave written informed consent.
CRP analysis
We determined the plasma CRP levels in fresh plasma
samples by using a high-sensitivity nephelometry assay
(CardioPhase hsCRP, code OQIY21, Dade Behring,
Deerfield, IL, USA) performed on a Behring Nephel-
o m e t e ro rah i g h - s e n s i t i v i t yt u r b i d i m e t r ya s s a y( C o d e
LX001, Dako, Glostrup, Denmark) performed on a
Konelab 60 analyzer. All analyses were performed in the
same laboratory at the Department of Clinical
Biochemistry, Herlev Hospital, Copenhagen University
Hospital. The detection limit was 0.17 mg/L for the
nephelometry assay and 0.20 mg/L for the turbidimetry
assay. Prior to the switch from the nephelometry to the
turbidimetry assay, the two assays were compared by
measuring plasma CRP with each method in 29 indivi-
duals. Spearman rank correlation coefficient between
the two CRP assays was 0.96, and a Wilcoxon signed-
rank test for difference between the two assays yielded a
P-value of 0.87. If measured CRP changed over calendar
time, due to analytical fluctuations, this could bias our
risk estimates, but we found no evidence for an interac-
tion between CRP level and date of measurement (=
diagnosis). When statistical analyses were run separately
by assay, the results were similar; we, therefore, only
present combined results in the paper. The assays were
assessed daily for precision by using internal controls
for each assay (coefficient of variation was 3% at a level
of 1.7 mg/L for the nephelometry assay and 6% at a
level of 2.1 mg/L for the turbidimetry assay) and
monthly for accuracy through a Scandinavian quality
control program.
Statistical analysis
The data were analyzed using STATA statistical soft-
ware (version 10.1; StataCorp, College Station, TX,
USA), and a two-sided P-value less than 0.05 was con-
sidered statistically significant. On the basis of the mea-
surements of plasma CRP with the nephelometry and
turbidemetry assays, we divided patients into assay-
Patients diagnosed with breast cancer in 
the period 1-1-2002 until 31-1-2009 
(n=3634)
• No CRP measurement (n=131)
• Men (n=23)
• In situ breast cancer (n=135)
• Surgery before blood sampling (n=137)
• CRP measurement >30 days before or 
after date of diagnosis (n=298)
Analysis of overall survival
(n=2910)
Analysis of disease-free 
survival and recurrence
(n=2783)
• No information about recurrence (n=72)
• Recurrence <90 days after date of 
diagnosis (n=15)
•Distant metastases at diagnosis (n=40)
• Patients enrolled after 31-12-2008 (no 
information about cause of death after 
this date) (n=38)
Analysis of death from 
breast cancer (n=2872)
Figure 1 Flowchart illustrating enrolment and exclusions. CRP, C-reactive protein.
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assay-specific tertiles into common tertiles of CRP. To
test the robustness of our findings, we used the same
approach to divide patients into octiles of CRP, and to
examine extremely high CRP levels, we divided patients
into five groups of CRP levels (0 to 25% percentile, 25
to 50% percentile, 50 to 75% percentile, 75 to 95% per-
centile, and ≥95% percentile). The decision to examine
t e r t i l e sa sw e l la sr o b u s t n e s susing octiles, and extreme
phenotypes was decided a priori,a sw eh a v ed o n ep r e -
viously in similar studies, but for other questions
[28,29].
To test whether covariates differed across tertiles of
plasma CRP, Kruskal-Wallis one-way analysis of var-
iance was used for continuous covariates and the chi
square test was used for categorical covariates. We used
the Kaplan-Meier method to plot overall survival, dis-
ease-free survival, or cumulative incidence of death from
breast cancer and recurrence against follow-up time and
used the log-rank test to test for differences across ter-
tiles of CRP. Cox proportional hazards regression mod-
els were used to estimate hazard ratios (HRs) and 95%
confidence intervals (CIs) of reduced overall and dis-
ease-free survival, death from breast cancer, and recur-
rence as a function of elevated plasma CRP levels.
Patients were censored at their date of death (or emigra-
tion), dates that are 100% complete in the Danish regis-
tries. We used a model that included age at diagnosis
only (Model 1), a multifactor-adjusted model that
included age at diagnosis, tumour size (≤20 mm, 20 to
50 mm, >50 mm, or unknown), lymph node status
(negative, positive, or unknown), presence of distant
metastases (yes, no, or unknown), tumour grade (well
differentiated, moderately differentiated, poorly/un-dif-
ferentiated, or unknown), estrogen receptor status (posi-
tive, negative, or unknown), progesterone receptor
status (positive, negative, or unknown), and HER2 status
(negative, positive, or unknown) (Model 2), and a multi-
factor-adjusted model that included the above-men-
tioned covariates and the lifestyle factors smoking (<10,
10 to 20, ≥20 cigarettes per day, or unknown), alcohol
consumption (≤168 or >168 grams per week, or
unknown), and body mass index (<18.5, 18.5 to 24.9, 25
to 29.9, or ≥30.0 kg/m
2,o ru n k n o w n )a sw e l la sm e n o -
pause status (pre-menopause, post-menopause, or
unknown) and cardiovascular disease (yes, no, or
unknown) (Model 3). For trend tests in log-rank and
Cox statistics, the CRP groups were coded 1, 2, 3, and
so on, corresponding to CRP tertiles and octiles.
For Cox proportional hazards regression analyses, we
assessed the assumption of proportional hazards graphi-
cally by plotting log(cumulative hazard) as a function of
follow-up time. We detected no major violations of the
proportional hazards assumption. Interactions between
tertiles of plasma CRP and covariates in the regression
models was tested for by computing a likelihood ratio
test comparing the statistical fit of models with and
without a two-factor interaction term.
Results
Baseline characteristics of the patients by CRP tertiles at
the time of diagnosis of breast cancer are shown in
Table 1. Levels of CRP were associated with several of
these characteristics. The median duration from date of
diagnosis to date of blood sampling was seven days (IQR,
two to nine days). Table 2 shows the risk of reduced over-
all and disease-free survival, death from breast cancer, and
recurrence by age at diagnosis, prognostic tumour charac-
teristics, lifestyle factors, menopause status, and presence
of cardiovascular disease. Causes of deaths in the present
cohort were breast cancer (64%), other cancer (11%), car-
diovascular disease (11%), respiratory disease (4%), other
disease (11%), and unknown cause (1%).
Overall survival
The overall survival among breast cancer patients
decreased with increasing levels of CRP (Figure 2A; log-
rank trend, P < 0.001). The five-year survival rates were
90%, 81%, and 74% among women in the lowest, middle,
and highest tertile of CRP. Corresponding age-adjusted
HRs were 1.00, 1.39 (95% CI, 1.04 to 1.85), and 2.13 (1.63
to 2.79); P for trend <0.001 (Figure 3). Multifactorial adjust-
ment for prognostic tumour characteristics (Model 2)
slightly reduced the HRs to 1.00, 1.28 (0.96 to 1.70), and
1.91 (1.46 to 2.50); P for trend <0.001. Additional adjust-
ment for lifestyle factors, menopause status, and cardiovas-
cular disease (Model 3) resulted in similar HRs of 1.00, 1.29
(0.96 to 1.72), and 1.84 (1.39 to 2.45); P for trend <0.001.
Disease-free survival
The disease-free survival among breast cancer patients
decreased with increasing levels of CRP (Figure 2B; log-
rank trend, P < 0.001). The five-year disease-free survi-
val rates were 87%, 80%, and 74% among women in the
lowest, middle, and highest tertile of CRP. Correspond-
ing age-adjusted HRs were 1.00, 1.25 (95% CI, 0.96 to
1.63), and 1.82 (1.42 to 2.34); P for trend < 0.001 (Figure
3). Multifactorial adjustment for prognostic tumour
characteristics (Model 2) slightly reduced the HRs to
1.00, 1.16 (0.89 to 1.51), and 1.70 (1.32 to 2.18); P for
trend <0.001. Additional adjustment for lifestyle factors,
menopause status, and cardiovascular disease (Model 3)
resulted in similar HRs of 1.00, 1.16 (0.88 to 1.52), and
1.65 (1.26 to 2.15); P for trend <0.001.
Death from breast cancer
The cumulative incidence of death from breast cancer
among breast cancer patients increased with increasing
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Page 4 of 13Table 1 Baseline characteristics of breast cancer patients by plasma levels of C-reactive protein
Tertiles of C-reactive protein (mg/L)
1st
(<1.04)
2nd
(1.04 to 3.24)
3rd
(>3.24)
P
No. of patients 975 966 969
Median age, years (IQR) 59 (48 to 68) 64 (55 to 73) 65 (56 to 74) <0.001
Tumour size, No. (%)
≤20 mm 587 (60) 487 (50) 427 (44)
20 to 50 mm 297 (30) 377 (39) 384 (40)
>50 mm 25 (3) 31 (3) 47 (5) <0.001
Unknown 66 (7) 71 (7) 111 (11)
Lymph node status, No. (%)
Lymph node negative 459 (47) 453 (47) 442 (44)
Lymph node positive 451 (46) 443 (46) 441 (46) 0.74
Unknown 65 (7) 70 (7) 106 (11)
Distant metastases, No. (%)
No 942 (97) 929 (96) 909 (94)
Yes 6 (1) 7 (1) 27 (3) <0.001
Unknown 27 (3) 30 (3) 33 (3)
Tumour grade, No. (%)
Well differentiated 248 (25) 243 (25) 194 (20)
Moderately differentiated 431 (44) 392 (41) 439 (45)
Poorly/un-differentiated 158 (16) 193 (20) 154 (16) 0.006
Unknown 138 (14) 138 (14) 182 (19)
Estrogen receptor status, No. (%)
Positive 766 (79) 744 (77) 723 (75)
Negative 146 (15) 150 (16) 140 (14) 0.90
Unknown 63 (6) 72 (7) 106 (11)
Progesterone receptor status, No. (%)
Positive 492 (50) 451 (47) 440 (45)
Negative 243 (25) 286 (30) 258 (27) 0.07
Unknown 240 (25) 229 (24) 271 (28)
HER2 status, No. (%)
Positive 279 (29) 260 (27) 268 (28)
Negative 82 (8) 68 (7) 70 (7) 0.76
Unknown 614 (63) 638 (66) 631 (65)
Cigarettes smoked per day, No. (%)
<10 689 (71) 624 (65) 531 (55)
10 to 20 91 (9) 110 (11) 141 (15)
≥20 61 (6) 80 (8) 110 (11) <0.001
Unknown 134 (14) 152 (16) 187 (19)
Alcohol consumption in grams per week*, No. (%)
≤168 786 (81) 743 (77) 702 (72)
>168 66 (7) 82 (8) 86 (9) 0.08
Unknown 123 (13) 141 (15) 181 (19)
Body mass index in kg/m
2†, No. (%)
<18.5 46 (5) 16 (2) 15 (2)
18.5 to 24.9 554 (57) 367 (38) 255 (26)
25 to 29.9 133 (14) 241 (25) 242 (25)
≥30 18 (2) 75 (8) 138 (14) <0.001
Unknown 224 (23) 267 (28) 319 (33)
Menopause status, No (%)
Post menopause 640 (66) 795 (82) 825 (85)
Pre menopause 325 (33) 159 (16) 130 (13) <0.001
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Page 5 of 13levels of CRP (Figure 2C; log-rank trend, P < 0.001)
reaching 11%, 19%, and 20% among women in the low-
est, middle, and highest tertile of CRP at the end of fol-
low-up. Corresponding age adjusted HRs were 1.00, 1.41
( 9 5 %C I ,0 . 9 8t o2 . 0 4 ) ,a n d2 . 1 2( 1 . 5 0t o2 . 9 9 ) ;P for
trend <0.001 (Figure 3). Multifactorial adjustment for
prognostic tumour characteristics (Model 2) slightly
reduced the HRs to 1.00, 1.22 (0.84 to 1.76), and 1.78
(1.26 to 2.52); P for trend = 0.001. Additional adjust-
ment for lifestyle factors, menopause status, and cardio-
vascular disease (Model 3) resulted in similar HRs of
1.00, 1.22 (0.84 to 1.78), and 1.66 (1.15 to 2.41); P for
trend = 0.005.
Recurrence
The cumulative incidence of recurrence among breast
cancer patients was highest among women in the high-
est tertile of CRP, but the incidence of recurrence did
not increase stepwise with increasing levels of CRP
(Figure 2D; log-rank trend, P = 0.24). The cumulative
incidence of recurrence at the end of follow-up was
7%, 6%, and 10% among women in the lowest, middle,
and highest tertile of CRP. Corresponding age adjusted
HRs were 1.00, 1.11 (95% CI, 0.70 to 1.76), and 1.53
(0.98 to 2.37); P for trend = 0.06 (Figure 3). The HRs
remained similar after multifactor-adjustment for prog-
nostic tumour characteristics and additional adjust-
ment for lifestyle factors, menopause status, and
cardiovascular disease.
Sensitivity analyses
Dividing CRP levels into octiles also resulted in a step-
wise increased risk of reduced overall survival (Figure 4;
P for trend <0.001). The multifactor-adjusted HR of
reduced overall survival among women in the highest
versus the lowest octile of CRP was 2.50 (95% CI, 1.52
to 4.10) (Figure 4). Compared to women with CRP
levels in the 0 to 25% percentile (<0.78 mg/L), the mul-
tifactor-adjusted HR of reduced overall survival was 3.59
(2.37 to 5.44) among women with CRP levels ≥95% per-
centile (≥16.4 mg/L) (Figure 4).
In sub-analyses stratified for age at diagnosis and
prognostic tumour characteristics, elevated CRP levels
across tertiles were associated with reduced overall sur-
vival irrespective of presence of distant metastases, and
estrogen and progesterone receptor status (Table 3).
Furthermore, elevated CRP levels were associated with
reduced overall survival separately in women above 57
years, with small and middle-sized tumours, positive
lymph node status, moderately and poorly/undifferen-
tiated tumours, and HER2 positive tumours. The multi-
factor-adjusted HR of reduced overall survival for the
highest versus the lowest tertile of CRP was 8.63 (2.04
to 36.4) among women with HER2 positive tumours.
However, tests of interaction between the CRP tertiles
and the prognostic factors were all non-significant, sug-
gesting that elevated CRP levels are associated with
similarly reduced overall survival irrespective of age at
diagnosis, tumour size, lymph node status, presence of
distant metastases, tumour grade, and estrogen receptor,
progesterone receptor, and HER2 status (Table 3).
Exclusion of patients with CRP values above 40 mg/L,
which likely reflect bacterial infection, resulted in similar
hazard ratios for all endpoints (data not shown).
Discussion
Using a prospective cohort study of 2,910 Danish
women with invasive breast cancer, we have demon-
strated that elevated CRP levels at the time of diagnosis
of breast cancer were associated with reduced overall
and disease-free survival and with increased risk of
death from breast cancer. These are novel observations.
Mechanistically, three components might explain the
observed association between elevated CRP levels and
poor breast cancer prognosis. First, tumour cell beha-
vior: plasma CRP levels may reflect the aggressiveness of
the tumour, that is, plasma CRP levels might sum up
some prognostic information of well-known tumour
characteristics, such as tumour stage and grade. In the
present study, elevated CRP levels were indeed asso-
ciated with larger tumour size, presence of distant
metastases, and lower tumour grade (although CRP was
Table 1 Baseline characteristics of breast cancer patients by plasma levels of C-reactive protein (Continued)
Unknown 10 (1) 12 (1) 14 (1)
Cardiovascular disease, No (%)
No 910 (93) 869 (90) 847 (87)
Yes 38 (4) 60 (6) 78 (8) <0.001
Unknown 27 (3) 37 (4) 44 (5)
Blood samples were drawn and CRP measured at time of diagnosis of breast cancer.
P-values were calculated using c
2 tests for categorical variables and Kruskal-Wallis one-way analysis of variance tests for continuous variables. For the evaluation
of P-values, patients with unknown values were excluded.
IQR = interquartile range.
*Cut-off values are based on the recommendation from of the Danish National Board of Health.
† Body mass index was calculated as weight in kilograms divided by height in meters squared.
Allin et al. Breast Cancer Research 2011, 13:R55
http://breast-cancer-research.com/content/13/3/R55
Page 6 of 13Table 2 Prognoses after diagnosis of breast cancer by tumour characteristics and lifestyle factors
Overall survival Disease-free survival Death from breast cancer Recurrence
Prognostic and lifestyle factors Hazard ratio (95% CI)
Age, years
<57 1.00 1.00 1.00 1.00
57 to 69 1.51 (1.12 to 2.03) 1.19 (0.90 to 1.56) 1.13 (0.79 to 1.62) 0.61 (0.40 to 0.93)
≥69 3.20 (2.45 to 4.18) 2.25 (1.76 to 2.87) 2.05 (1.49 to 2.82) 0.56 (0.36 to 0.88)
Tumour size, mm
≤20 1.00 1.00 1.00 1.00
20 to 50 2.39 (1.89 to 3.01) 2.12 (1.72 to 2.62) 3.27 (2.37 to 4.51) 1.49 (1.03 to 2.17)
>50 3.48 (2.22 to 5.44) 2.44 (1.53 to 3.90) 4.27 (2.33 to 7.82) 0.95 (0.30 to 3.03)
Lymph node status
Lymph node negative 1.00 1.00 1.00 1.00
Lymph node positive 1.47 (1.18 to 1.84) 1.48 (1.21 to 1.82) 2.49 (1.81 to 3.43) 2.08 (1.41 to 3.07)
Distant metastases
No 1.00 NA 1.00 NA
Yes 8.57 (5.61 to 13.1) NA 12.32 (7.66 to 19.80) NA
Histopathological grade
Well differentiated 1.00 1.00 1.00 1.00
Moderately differentiated 1.64 (1.19 to 2.26) 1.57 (1.16 to 2.11) 2.52 (1.53 to 4.13) 1.94 (1.05 to 3.59)
Poorly/un-differentiated 2.76 (1.96 to 3.90) 3.00 (2.18 to 4.12) 5.28 (3.17 to 8.79) 5.32 (2.87 to 9.87)
Estrogen receptor status
Positive 1.00 1.00 1.00 1.00
Negative 2.09 (1.63 to 2.66) 1.98 (1.57 to 2.49) 3.03 (2.24 to 4.10) 2.31 (1.54 to 3.47)
Progesterone receptor status
Positive 1.00 1.00 1.00 1.00
Negative 2.32 (1.77 to 3.05) 2.02 (1.58 to 2.60) 3.28 (2.25 to 4.77) 1.91 (1.23 to 2.95)
HER2 receptor status
Positive 1.00 1.00 1.00 1.00
Negative 2.46 (1.38 to 4.39) 2.06 (1.21 to 3.52) 2.72 (1.30 to 5.69) 1.49 (0.58 to 3.85)
No. of cigarettes smoked per day
<10 1.00 1.00 1.00 1.00
10 to 20 1.30 (0.97 to 1.75) 1.15 (0.86 to 1.54) 1.55 (1.09 to 2.21) 0.96 (0.55 to 1.66)
≥20 1.06 (0.74 to 1.51) 0.96 (0.68 to 1.36) 0.81 (0.49 to 1.37) 0.73 (0.37 to 1.45)
Alcohol consumption in grams per week*
≤168 1.00 1.00 1.00 1.00
>168 0.79 (0.53 to 1.19) 0.72 (0.48 to 1.08) 0.96 (0.59 to 1.55) 0.83 (0.42 to 1.65)
Body mass index in kg/m
2†
<18.5 2.21 (1.37 to 3.57) 2.09 (1.31 to 3.32) 1.10 (0.48 to 2.52) 0.32 (0.04 to 2.29)
18.5 to 24.9 1.00 1.00 1.00 1.00
25 to 29.9 1.06 (0.80 to 1.40) 1.09 (0.84 to 1.42) 1.05 (0.74 to 1.49) 1.16 (0.74 to 1.82)
≥30 1.45 (1.01 to 2.09) 1.58 (1.13 to 2.21) 1.62 (1.05 to 2.52) 1.88 (1.08 to 3.25)
Menopause status, No (%)
Post menopause 1.00 1.00 1.00 1.00
Pre menopause 0.36 (0.26 to 0.51) 0.56 (0.42 to 0.74) 0.52 (0.36 to 0.77) 1.64 (1.12 to 2.42)
Cardiovascular disease, No (%)
No 1.00 1.00 1.00 1.00
Yes 2.46 (1.77 to 3.42) 2.32 (1.67 to 3.22) 1.70 (1.03 to 2.79) 1.45 (0.71 to 2.98)
*Cut-off values are based on the recommendation from of the Danish National Board of Health.
† Body mass index was calculated as weight in kilograms divided by height in meters squared.
Hazard ratios are unadjusted.
NA: not applicable.
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Page 7 of 13not linearly associated with tumour grade), and these
prognostic factors were associated with poor prognosis.
Second, adjacent inflammation: plasma CRP levels might
express the magnitude and the nature of any inflamma-
tion in the breast tumour microenvironment. Inflamma-
tory pathways play important roles in all stages of
tumourigenesis, including tumour initiation and promo-
tion, malignant transformation, tumour invasion, and
metastasis [3-6]. Thus, solid tumours typically trigger
inflammatory responses that result in the formation of a
pro-tumourigenic and pro-angiogenic microenvironment
around the tumour. Immune and inflammatory cells in
the tumour microenvironment interact with malignant
cells in a complicated fashion, the net result of which is
stimulation of tumour growth, invasion, and metastasis
[5-9]. Despite the fact that breast cancers rarely are
characterized by significant histological inflammation,
inflammation might also play a role in breast cancer
prognosis [15-20]. Thus, macrophage infiltration into
invasive breast carcinomas was associated with high vas-
cularity of the breast tumour as well as with reduced
recurrence-free and overall survival [18], and targeting
of cancer associated fibroblasts resulted in favourable
changes of the immune tumour microenvironment and
improved anti-metastatic effects of doxorubicin che-
motherapy in a murine model of metastatic breast can-
cer [19]. Furthermore, a recently published study
showed that blockade of the IL-8 receptor selectively
targets breast cancer stem cells and retards tumour
growth and reduces metastasis [17]. Third, host beha-
viour: plasma CRP levels may outline the general health
of the woman at the time of diagnosis of breast cancer.
In the present study, elevated CRP levels were indeed
associated with smoking and elevated body mass index
at the time of diagnosis. However, whereas smoking was
not associated with poor breast cancer prognosis, body
mass index <18.5 or ≥30 at the time of diagnosis was
associated with poor prognosis. Previous studies have
shown that elevated CRP levels are associated with all-
cause mortality in the general population [29,30]. Thus,
it is possible that the present finding of an association
between elevated CRP levels at the time of diagnosis of
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C. Death from breast cancer after a breast cancer diagnosis
Time since diagnosis, years
02468
C
u
m
u
l
a
t
i
v
e
 
i
n
c
i
d
e
n
c
e
 
o
f
d
e
a
t
h
 
f
r
o
m
 
b
r
e
a
s
t
 
c
a
n
c
e
r
,
 
%
0
5
10
15
20
25 Log rank trend, P<0.001
CRP tertiles
1st
2nd
3rd
Figure 2 Overall survival (A), disease-free survival (B), death from breast cancer (C), and cumulative incidence of recurrence after a
breast cancer diagnosis (D). Results are shown by tertiles of plasma C-reactive protein (CRP) and are based on 2,910 women from the
Copenhagen Breast Cancer Study who were observed for up to seven years.
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Page 8 of 13breast cancer and overall survival may not be breast
cancer specific but can simply be due to CRP acting as
a general marker of health and longevity. However, as
64% of the deaths in the present study were due to
breast cancer, breast cancer was the leading cause of
death in the present cohort. The fact that the observed
association between elevated CRP levels and increased
risk of death from breast cancer was of the same magni-
tude as the observed association between elevated CRP
levels and overall survival suggest that CRP may indeed
be associated with mortality through a breast-cancer-
related mechanism. Elevated plasma CRP is a well-
known marker of cardiovascular disease [31], which
could imply that elevated CRP levels are associated with
overall survival through the association with cardiovas-
cular disease. However, the fact that only 11% of the
deaths in the present cohort were due to cardiovascular
diseases and the fact that we adjusted for cardiovascular
disease at baseline limit the possibility that our finding
on overall survival is severely confounded by deaths
from cardiovascular disease.
Our findings of a positive association between elevated
CRP levels and poor breast cancer prognosis are in con-
trast to negative studies with 110 to 300 patients
[25,26], but are indirectly supported by findings from
other studies with 85 to 734 patients which did report a
positive association [21-24]. The largest study so far
which comprised approximately 700 women treated suc-
cessfully for early stage breast cancer found that ele-
vated levels of CRP measured two and a half years after
the time of diagnosis were associated with reduced dis-
ease-free and overall survival [23]. Thus, the combined
evidence from this and our own study suggests that ele-
vated plasma CRP levels are associated with short-term
as well as long-term prognosis after breast cancer.
Whereas studies that measure CRP after diagnosis and
treatment reflect long-term prognosis, studies that mea-
sure CRP at the time of diagnosis more likely reflect
Model 1 Model 2 Model 3
Hazard ratio (95% CI)
0.5 1.0 1.5 2.0 2.5 3.0
Hazard ratio (95% CI)
0.5 1.0 1.5 2.0 2.5 3.0
Hazard ratio (95% CI)
0.5 1.0 1.5 2.0 2.5 3.0
Patients Events
Hazard ratio 
(95% CI)
P, 
trend
Hazard ratio 
(95% CI)
P, 
trend
Hazard ratio 
(95% CI)
P, 
trend
1st (<1.04) 975 78 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
2nd (1.04-3.24) 966 122 1.39 (1.04-1.85) 1.28 (0.96-1.70) 1.29 (0.96-1.72)
3rd (>3.24) 969 183 2.13 (1.63-2.79) 1.91 (1.46-2.50) 1.84 (1.39-2.45)
1st (<1.04) 944 97 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
2nd (1.04-3.24) 930 129 1.25 (0.96-1.63) 1.16 (0.89-1.51) 1.16 (0.88-1.52)
3rd (>3.24) 909 181 1.82 (1.42-2.34) 1.70 (1.32-2.18) 1.65 (1.26-2.15)
1st (<1.04) 964 49 1 (reference) <0.001 1 (reference) 0.001 1 (reference) 0.005
2nd (1.04-3.24) 950 72 1.41 (0.98-2.04) 1.22 (0.84-1.76) 1.22 (0.84-1.78)
3rd (>3.24) 958 104 2.12 (1.50-2.99) 1.78 (1.26-2.52) 1.66 (1.15-2.41)
1st (<1.04) 944 39 1 (reference) 0.06 1 (reference) 0.10 1 (reference) 0.24
2nd (1.04-3.24) 930 35 1.11 (0.70-1.76) 0.99 (0.62-1.58) 0.93 (0.57-1.50)
3rd (>3.24) 909 44 1.53 (0.98-2.37) 1.45 (0.93-2.26) 1.32 (0.82-2.12)
Tertiles of CRP 
(CRP, mg/L)
Reduced overall survival after a 
breast cancer diagnosis
Reduced disease-free survival after a 
breast cancer diagnosis
Recurrence after a breast cancer 
diagnosis
Death from breast cancer after a 
breast cancer diagnosis
Figure 3 Risk of reduced overall survival, disease-free survival, and recurrence after a breast cancer diagnosis. Hazard ratios by tertiles
of plasma C-reactive protein (CRP) are based on 2,910 women from the Copenhagen Breast Cancer Study who were observed for up to seven
years after a diagnosis of breast cancer. Model 1: adjusted for age at diagnosis. Model 2: adjusted for age at diagnosis, tumour size, lymph node
status, presence of distant metastases, tumour grade, and estrogen receptor, progesterone receptor, and HER2 status. Model 3: adjusted for the
above-mentioned covariates and smoking, alcohol consumption, body mass index, menopausal status, and cardiovascular disease.
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Page 9 of 13breast cancer specific survival. In fact, approximately
55% of the deaths, 60% of the deaths from breast cancer,
and 68% of the recurrences in the present study
occurred during the first two and a half years after a
diagnosis of breast cancer. Therefore, our results may
not be comparable to studies that have measured CRP
after diagnosis and treatment.
The large sample size of our study allowed us to stra-
tify for well-established prognostic tumour characteris-
tics, and interestingly our data suggest that elevated
CRP levels are associated with reduced overall survival
irrespective of age at diagnosis, tumour size, lymph
node status, presence of distant metastases, tumour
grade, and estrogen receptor, progesterone receptor, and
HER2 status. However, we observed a very strong asso-
ciation between elevated CRP levels and reduced overall
survival among women with positive HER2 status which
may warrant further investigation by future studies.
Dividing plasma CRP levels into octiles resulted in a
stepwise increased risk of reduced overall survival,
demonstrating the robustness of the observed associa-
tion between elevated CRP levels and risk of reduced
overall survival. Furthermore, we observed that com-
pared to women with CRP levels in the 0 to 25% per-
centile (CRP <0.78 mg/L), women with CRP levels ≥95%
percentile (≥16.4 mg/L) had a 3.5-fold increased risk of
reduced overall survival, suggesting that women with
high CRP levels at the time of diagnosis have a particu-
larly poor survival.
Although the age-adjusted HR for recurrence for the
highest versus the lowest tertile of CRP was borderline sig-
nificant, we did not detect a statistically significant associa-
tion between elevated CRP levels and recurrence of breast
cancer, which may suggest that no such association exists.
However, as we only detected 118 recurrences in our study
in contrast to 383 deaths, it is also possible that our statisti-
cal power was too small to detect an association. There-
fore, other, larger studies are needed to answer
unequivocally whether increased CRP levels at the time of
diagnosis associate with recurrence of breast cancer or not.
As CRP is one of several acute-phase proteins, whose
concentrations increase during acute or chronic inflam-
mation, other inflammation-related biomarkers may also
be associated with breast cancer prognosis. Prior studies
have reported that lower serum albumin concentrations
[25], elevated serum amyloid A concentrations [23], and
elevated YKL-40 concentrations [32] are all associated
with poor breast cancer prognosis.
S of a r ,t h ep r e s e n ts t u d yi sb yf a rt h el a r g e s ts t u d y
that has examined whether an association exists between
Model 1 Model 2 Model 3
Hazard ratio (95% CI)
12345678
Hazard ratio (95% CI)
12345678
Hazard ratio (95% CI)
12345678
>95% (>16.4)
Patients Events
Hazard ratio 
(95% CI)
P, 
trend
Hazard ratio 
(95% CI)
P, 
trend
Hazard ratio 
(95% CI)
P, 
trend
1st (<0.44) 364 22 1 (reference) <0.001 1 (reference) <0.001 1 (reference) <0.001
2nd (0.44-0.78) 364 28 1.06 (0.61-1.86) 1.05 (0.60-1.84) 1.07 (0.61-1.88)
3rd (0.79-1.19) 367 40 1.36 (0.81-2.30) 1.26 (0.75-2.13) 1.27 (0.75-2.15)
4th (1.20-1.78) 362 44 1.59 (0.95-2.67) 1.53 (0.91-2.55) 1.63 (0.97-2.75)
5th (1.79-2.80) 363 50 1.74 (1.05-2.88) 1.54 (0.93-2.55) 1.58 (0.95-2.65)
6th (2.81-4.53) 363 54 1.88 (1.14-3.10) 1.82 (1.10-3.00) 1.80 (1.08-3.00)
7th (4.54-8.10) 364 59 2.09 (1.27-3.42) 1.92 (1.17-3.15) 1.94 (1.16-3.24)
8th (>8.10) 363 86 3.17 (1.97-5.09) 2.58 (1.60-4.16) 2.50 (1.52-4.10)
725 50 1 (reference) 1 (reference) 1 (reference)
734 84 1.41 (0.99-2.01) 1.34 (0.94-1.90) 1.36 (0.95-1.94)
725 103 1.72 (1.22-2.42) 1.60 (1.14-2.26) 1.58 (1.11-2.25)
581 96 2.03 (1.43-2.87) 1.81 (1.28-2.56) 1.76 (1.22-2.54)
145 50 4.99 (3.36-7.41) 3.93 (2.63-5.88) 3.59 (2.37-5.44)
Octiles of CRP 
(CRP, mg/L)
0-25% (<0.78)
25-50% (0.78-1.78)
50-75% (1.79-4.54)
75-95% (4.55-16.3)
Percentiles of CRP
(CRP, mg/L)
Figure 4 Risk of reduced overall survival after a breast cancer diagnosis. Hazard ratios by octiles or extreme levels of plasma C-reactive
protein (CRP) are based on 2,910 women from the Copenhagen Breast Cancer Study who were observed for up to seven years after a diagnosis
of breast cancer. Model 1: adjusted for age at diagnosis. Model 2: adjusted for age at diagnosis, tumour size, lymph node status, presence of
distant metastases, tumour grade, and estrogen receptor, progesterone receptor, and HER2 status. Model 3: adjusted for the above-mentioned
covariates and smoking, alcohol consumption, body mass index, menopausal status, and cardiovascular disease.
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Page 10 of 13CRP levels at the time of diagnosis and breast cancer
prognosis. However, certain limitations must be
acknowledged. Although we did adjust for potential con-
founders, we cannot exclude residual confounding by
factors not taken into account, such as socioeconomic
status, physical activity, and treatment, or by imperfectly
or incompletely measured confounders. Since patients
are referred to different treatment regimes on the basis
of tumour characteristics, which we did adjust for, it
seems unlikely that our results are confounded by differ-
ences in treatment. Also, we did not measure serum
amyloid A, which has previously been associated with
an even stronger increase in risk of death than CRP
[ 2 3 ] .F i n a l l y ,s i n c et h ep r e s e n ts t u d yi sas i n g l e - c e n t e r
study of Danish women diagnosed with breast cancer,
our findings may not necessarily apply to other ethnic
groups. Since our department for breast surgery treats
all patients with breast cancer from a geographically
well-defined area of Copenhagen regardless of severity
or sub-diagnosis, our results may indeed be generalized
to comparable populations of unselected patients with
breast cancer.
Conclusions
In conclusion, in 2,910 Danish women with invasive
breast cancer, elevated CRP levels at the time of diagno-
sis of breast cancer were associated with reduced overall
and disease-free survival and with increased risk of
Table 3 Risk of reduced overall survival by plasma levels of C-reactive protein and prognostic factors
Tertiles of C-reactive protein (mg/L)
Stratification No. of patients No. of deaths P, inter-action 1st (<1.04) 2nd (1.04 to 3.24) 3rd (>3.24) P, trend
Multifactor-adjusted hazard ratio (95% CI)
None 2,910 383 1.0 1.29 (0.96 to 1.72) 1.84 (1.39 to 2.45) <0.001
Age at diagnosis
<57 years 964 74 0.40 1.0 0.97 (0.49 to 1.90) 1.69 (0.91 to 3.14) 0.08
57 to 69 years 964 103 1.0 1.76 (0.99 to 3.11) 2.53 (1.42 to 4.50) 0.002
≥69 years 982 206 1.0 1.18 (0.78 to 1.79) 1.59 (1.07 to 2.37) 0.01
Tumour size
≤20 mm 1,501 119 0.33 1.0 1.02 (0.62 to 1.68) 1.66 (1.03 to 2.68) 0.03
20 to 50 mm 1,409 264 1.0 1.48 (1.02 to 2.15) 2.04 (1.41 to 2.95) <0.001
>50 mm 103 23 1.0 2.74 (0.36 to 20.7) 0.63 (0.06 to 6.61) 0.44
Lymph node status
Lymph node negative 1,334 132 0.59 1.0 1.07 (0.65 to 1.76) 1.48 (0.92 to 2.38) 0.08
Lymph node positive 1,335 191 1.0 1.55 (1.01 to 2.38) 2.04 (1.33 to 3.12) 0.001
Distant metastases
No 2,780 343 0.66 1.0 1.31 (0.96 to 1.78) 1.80 (1.33 to 2.44) <0.001
Yes 40 23 1.0 0.50 (0.01 to 21.0) 15.6 (1.10 to 221) 0.03
Tumour grade
Well differentiated 685 50 0.69 1.0 0.74 (0.31 to 1.75) 1.49 (0.68 to 3.28) 0.21
Moderately differentiated 1,262 154 1.0 1.17 (0.74 to 1.88) 1.78 (1.14 to 2.77) 0.007
Poorly/un-differentiated 505 92 1.0 2.19 (1.16 to 4.14) 2.23 (1.14 to 4.39) 0.03
Estrogen receptor status
Positive 2,233 234 0.83 1.0 1.07 (0.74 to 1.55) 1.59 (1.11 to 2.28) 0.005
Negative 436 88 1.0 2.07 (1.08 to 3.98) 2.74 (1.44 to 5.19) 0.002
Progesterone receptor status
Positive 1,383 87 0.60 1.0 1.83 (0.93 to 3.59) 2.37 (1.23 to 4.58) 0.01
Negative 787 130 1.0 1.47 (0.88 to 2.47) 2.22 (1.33 to 3.71) 0.002
HER2 status
Positive 807 29 0.11 1.0 1.64 (0.34 to 7.96) 8.63 (2.04 to 36.4) <0.001
Negative 220 19 1.0 1.24 (0.24 to 6.49) 1.29 (0.31 to 5.45) 0.74
Blood samples were drawn and CRP measured at time of diagnosis of breast cancer.
Hazard ratios are multifactor-adjusted for age at diagnosis, tumour size, lymph node status, presence of distant metastases, tumour grade, and estrogen receptor,
progesterone receptor, and HER2 status, smoking, alcohol consumption, body mass index, menopause status, and cardiovascular disease (Model 3), excluding the
factor stratified for; however, age stratified analyses were still adjusted for age.
Due to differences in numbers of missing values for the covariates in question, numbers of patients and deaths do not necessarily add up to 2,910 and 383,
respectively.
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Page 11 of 13death from breast cancer, independently of well-estab-
lished prognostic tumour characteristics and lifestyle
factors.
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